Clinical evaluation of moxalactam

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Microbiology

Background:

• Moxalactam is a novel beta-lactam antibiotic.
• Serious bacterial infections require effective antimicrobial therapy.

Purpose of the Study:

• To evaluate the efficacy and safety of moxalactam in patients with severe infections.
• To assess moxalactam's pharmacokinetic profile at different dosages.

Main Methods:

• 45 patients with various infections received moxalactam intravenously or intramuscularly (1-12 g/day).
• Bacterial isolates included Enterobacteriaceae, Pseudomonas aeruginosa, Staphylococcus aureus, and anaerobes.
• Pharmacokinetic data were collected at 0.5 hours post-infusion for different doses.

Main Results:

• Clinical cure was observed in 15 patients, with 8 showing improvement.
• 13 patients experienced relapses or superinfections; 10 patients failed therapy.
• Mean 0.5-h postinfusion levels varied by dose (105 µg/ml for 4g, 44.7 µg/ml for 2g, 18 µg/ml for 1g).
• Emergence of resistant organisms (Pseudomonas, enterococci, Candida) occurred in 17 patients.

Conclusions:

• Moxalactam demonstrated generally favorable results in complicated infections.
• Minimal toxicity was observed, primarily reversible eosinophilia and mild liver function abnormalities.
• The emergence of resistant organisms is a significant concern requiring further investigation.